Innovent Biologics Inc., of Hong Kong, completed a $150 million series E round of financing. The round was led by Capital Group Private Markets with its $90 million investment. New investors, including Cormorant Asset Management, Rock Springs Capital and Ally Bridge Group, and existing investors such as Temasek, Hillhouse, Legend Capital, Lilly Asia Venture and Taikang Insurance, also participated in the funding.